KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash & Equivalents: 2013-2025

Historic Cash & Equivalents for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to $555.3 million.

  • Xenon Pharmaceuticals' Cash & Equivalents rose 533.70% to $555.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $555.3 million, marking a year-over-year increase of 533.70%. This contributed to the annual value of $754.4 million for FY2024, which is 407.53% up from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Cash & Equivalents stood at $555.3 million for Q3 2025, which was down 11.14% from $624.8 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Cash & Equivalents registered a high of $754.4 million during Q4 2024, and its lowest value of $57.2 million during Q4 2022.
  • In the last 3 years, Xenon Pharmaceuticals' Cash & Equivalents had a median value of $116.7 million in 2025 and averaged $247.0 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Cash & Equivalents slumped by 82.55% in 2023 and then spiked by 533.70% in 2025.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Cash & Equivalents stood at $175.7 million in 2021, then crashed by 67.42% to $57.2 million in 2022, then spiked by 159.67% to $148.6 million in 2023, then spiked by 407.53% to $754.4 million in 2024, then surged by 533.70% to $555.3 million in 2025.
  • Its Cash & Equivalents stands at $555.3 million for Q3 2025, versus $624.8 million for Q2 2025 and $116.7 million for Q1 2025.